Scholar Rock gets FDA nod to trial SMA drug with GLP-1ra in obesity

Scholar Rock will be initiating a Phase II trial of its spinal muscular atrophy pipeline drug apitegromab alongside a GLP-1 receptor agonist (GLP-1ra) in patients with obesity months after being given the green light by the US Food and Drug Administration (FDA).